Ameliorative Potential of Ursolic Acid Isolated from Morina coulteriana Royale Targeting P53 Gene Mutation Induced by Cyclophosphamide

Objective: More than 50% of human cancers show mutated TP53 gene. Reactivation or restoration of p53 mutations is viewed as a potential approach for treating cancer. The objective of the present study was to determine whether ursolic acid (UA) could effectively restore the p53 mutations to their wild type or normal state and upregulate its expression. Methods: The animals were divided into 3 groups, each with 10 mice. Group I was the negative control which received normal saline with 1% dimethyl sulfoxide (DMSO). Group II was the positive control which received cyclophosphamide (CP) (50mg/kg bw) intrapritonealy for 4 days continuously after which the animals were kept on normal saline for the rest 10 days. The treatment group received cyclophosphamide (CP) initially for the first 4 successive days intraperitoneally (50mg/kg bw) and then ursolic acid (UA) (60 mg/kg bw) orally for the next 10 days (post-treatment). Isolated DNA was used in Sanger sequencing of the polymerase chain reaction (PCR) amplified product of the TP53 gene. Results: Our study demonstrated that UA treatment post CP injection had a restoration efficacy of 89.08%. The molecule, in this investigation, was able to restore the wild type (normal) conformation to the mutations induced by cyclophosphamide in the TP53 gene. 89.08 % mutations converted back to their normal or wild-type forms in the treatment group. Conclusion: Several investigations have been carried out on this molecule and have indicated UA as a promising chemopreventive agent. The most frequently mutated gene in any type of cancer is the tumor suppressor p53 and UA has shown a potential in functional restoration of the mutated p53 protein. p53 is known to play a vital role in apoptosis and the p53 dependent apoptotic pathway is of prime importance in cancer therapy. Though there has been pioneering work on PRIMA-1 and thiosemicarbazones, identification and development of additional molecules is required.

 Introduction

Acting as the major barrier to the malignant transformations and tumor progression, p53 tumor suppressor gene is truly called the “Guardian of the genome”. p53 plays a pivotal role in regulating the cell division and growth, apoptosis and cell cycle blockade, senescence or differentiation in response to varied environmental stresses, thus maintaining the genetic stability. Other roles assigned to p53 include, DNA damage correction, autophagy, proliferation [1-3], inhibition of epithelial to mesenchymal transition and other activities preceding metastasis [4-6].

In recent years it has been studied that the primary target and the frequently altered gene by the environmental mutagens, of most human and animal cancers has been the TP53 gene encoding p53 protein. Mutations in other tumor suppressor genes generally include deletion or truncation leading to cancer. However, the mutations in TP53 allele are predominantly missence mutations leading to the expression of full length p53 mutant protein. Majority of the tumor suppressor genes like RB, APC, BRCA1, get inactivated when mutated, however TP53 when mutated, in addition to the loss of wild type p53 functions, in a dominant negative (DN) manner forms heterotetramers with the unmutated wild type p53 expressed from the other wild type alleles [7, 8]. In short, the mutation in wild type p53 leads to the neomorphic gain of function (GOF) [9] in p53. p53 in this case loses its wild type function and gains a new dominant phenotypic expression which actually contributes to the acquisition of oncogenic properties [10, 11]. Most important addition to it is that the mutation in the TP53 gene could diminish the effectiveness of chemotherapy including agents like doxorubicin, tenozolomide, tamoxifen and gemcitabine [12]. Several studies have explained this occurrence of drug resistance [13]. The inactivation of p53 is the prior requirement for the cancer progression [14-16]. Therefore reactivation of the p53 mutations appears to be an attractive strategy for cancer therapy. Restoration of the wild-type functions should not only re-enable tumor suppressor function but also eliminate the oncomorphic gain of function of the mutant p53. Owing to p53’s critical role in therapy response, in recent years, many promising studies have been proposed where in mutant p53 function has been re-established by certain drug leads [14, 17-21]. One such compound is the APR-246, also known as eprenetapopt or PRIMA-1MET, a derivative of PRIMA 1, which is the most studied of these compounds and has advanced to several clinical studies. Although several such molecules have been identified, additional classes of compounds are highly required.

Cancer has been the leading cause of deaths in the world with 9.6 million deaths recorded in 2018 [22]. Even the conventional therapies for cancer like chemotherapy, radiotherapy, endocrine therapy and targeted therapy have their serious limitations which include severe side effects and dose limiting toxicities [23]. In the past few years, this approach has shifted to the diverse flora breathing in the nature which has shown its potential in treating a huge variety of diseases including cancer from time to time. The chemopreventive agents produced by the plants are the various secondary meatbolites such as polyphenols, isoprenoids, alkaloids, sulphoraphanes and certain vitamins and their precursors [24, 25].

Terpenes are one such class of compounds which have a wide occurrence in the flora on earth [26]. Ursolic acid (UA) is a natural pentacyclic triterpenoid compound possessing diverse pharmacological activities including neuroprotection, anticancer, antimicrobial, hepatoprotection, anti-inflammatory, antioxidative and regulating blood glucose [27-30].

This study involved the study of ameliorative effect of the isolated molecule, ursolic acid from a promising antimutagenic plant Morina coulteriana, on p53 expression against the cyclophosphamide induced mutations.

Materials and Methods <italic id="italic-2d94637e2abdbbee8e257a17be8c5d01">Materials<italic id="italic-2"/></italic>

Cyclophosphamide (CP) was obtained from Sigma Aldrich Co. Oligonucleotide primers were synthesized by Biokart India Pvt. Ltd., Karnataka, India. Ursolic Acid was isolated from the plant Morina coulteriana using chromatographic techniques. Purity of the compound was determined by 13CNMR (Carbon-13 nuclear magnetic resonance) and HPLC (high-performance liquid chromatography). All others chemicals used in the experiment were of analytical grade from Sigma Aldrich.

<italic id="italic-4">Experimental design<italic id="italic-5"/></italic>

Thirty, 6-8 week old, Balb/c mice with body weight 25-30 g of both the sexes were used in the experiment. The animals were procured from the Indian Institute of Integrative Medicine (IIIM), Jammu, J & K. The animals were maintained under standard conditions of temperature (22±2º C) and relative humidity (55±10 %) with 12 h light/ dark cycle. The animals were given standard pellet diet and water ad libitum. The whole experiment was carried out according to the guidelines given by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). The experiment was approved by the Institutional Animals Ethics Committee [F (IAEC- Approval) KU/2017/21].

The animals were allocated into 3 groups, each of 10 mice. Group I was the negative control which received normal saline (with 1% DMSO). Group II was the positive control which received cyclophosphamide (50mg/kg bw) intraperitonealy for 4 days continuously after which the animals were kept on normal saline for the rest 10 days. Group III was the treatment group which received CP initially for the first 4 successive days and then UA (60 mg/kg bw) for the next 10 days.

<italic id="italic-7">Sampling<italic id="italic-8"/></italic>

24 h post last treatment, 65-100 µl of blood was taken by retro-orbital bleed with a heparinized microcapillary tube from the animals. Blood was immediately stored into a 1.5 ml microfuge tube containing 20 µl of 10 mM EDTA (ethylenediaminetetraacetic acid) and stored at -80º C (for PCR and sequence analysis).

<italic id="italic-9">Genomic DNA isolation<italic id="italic-10"/></italic>

DNA was isolated from the blood by retro-orbital bleed using the method adapted from Higuchi (1989) [31].

<italic id="italic-11">Evaluation of the quantity and quality of isolated DNA<italic id="italic-12"/></italic>

The amount of DNAisolated was spectrophotometrically (Nanodrop Technologies, Inc., Wilmington, DE, USA) estimated by measuring its optical density (OD) at 260 nm and the purity was assessed as the ratio of absorbance at 260 and 280 nm (A260/A280). The integrity of the isolated DNA was assessed by electrophoresis in 1x Tris-acetate-EDTA buffer (TAE) using 0.8% agarose gel with 2.5µl of ethidium bromide in it. The gel was visualized by a Gel Doc system (Alphaimager TM 2200, Alpha Innotech Corporation) under UV light.

Amplification of the tp53 gene was achieved by polymerase chain reaction (PCR) using a forward primer P53 5´TGCTCACCCTGGCTAAAGTT-3´ and the reverse primer p53 5´AATGTCTCCTGGCTCAGAGG-3´.

<italic id="italic-8844fa7c53d97d65328d8be774fc4f7e">DNA sequencing (Sanger Sequencing)<italic id="italic-14626b04944a162f805de99d5ed14ce3"/></italic>

The sequencing was commercially done using the services of Biokart India Pvt. Ltd., Bangaluru. For purification and sequencing, 20 μl of unpurified product samples were given.

<italic id="italic-a359ca310c0d30223f97de04f238ef1d">Statistical analysis<italic id="italic-c0717b0e73c1628278c90e65327fa4cc"/></italic>

Average data generated for the treatment group was compared to the respective data of the positive control group. The test results were expressed as mean and standard deviation using Mann-Whitenny U test in Graph- pad prism (10.3.0.)

Results

Ursolic acid was isolated from the ethyl acetate fraction of the crude extract of plant Morina coulteriana Royale, collected from Zaznar, Mughal Road, Kashmir (J&K). The plant was identified at the Centre for Biodiversity and Taxonomy and voucher specimen [No. 2634 (KASH)] was preserved in the herbarium. UA was characterized by different spectroscopic techniques and was stored at -20 ºC before being used in the present study. Its structure is shown in Figure 1.

As revealed by the Sanger sequence analysis of the amplified PCR products, the negative control group (Group I) which received normal saline (with 1% DMSO) throughout the whole experiment did not show any mutation. The chromatograms from the negative control group show no change in the base sequence hence, no mutations. However the positive control group (Group II) that received the alkylating agent, cyclophosphamide (CP), for 4 days and normal saline for the rest 10 days showed mutations in the TP53. It is because TP53 is considered a major target of CP. The frequency of mutations in the TP53 was majorly (72.41%) transversions and 27.59% tansitions. The major transversions being G→C (28.16%) and G→T (21.83%). However other transversions that occurred were A→C, A→T, C→G. On the other hand, G→A (22.98%) and T→C (4.59%) added to the transition mutations in the gene.

On the other hand, the treatment group that was given CP for the first 4 days and UA for the next 10 days, showed a significant decline in the mutations. In other words, it was able to restore the functionality of the p53 protein by about 89.08 %. Treatment with ursolic acid reversed these mutations to the wild type showing a powerful antimutagenic efficacy. The positions at which the transversions or transitions had occurred showed a reversal to the normal conformation e.g the G→C transversion mutation in the positive control showed a C→G reversal in the treatment group or a G→A transition mutation in the positive control showed A→G reversal in the treatment group. In totality, 89.08 % mutations converted back to their normal or wild-type forms. The difference between the positive control group and the treatment group was recorded to be statistically significant (p<0.0001). The sequencing results for p53 can be viewed in the given chromatograms (Figure 2, 3 and 4).

Discussion

Research in the last 40 years, has established that the p53 tumor suppressor plays a significant role in preventing the growth of tumors and neoplastic transformation by acting as an exceptionally sensitive stress sensor and coordinating a complex network of various effector pathways and processes that safeguard genome stability and cellular homeostasis. Also, in human malignancies, missense mutations in the TP53 gene are incredibly common. These mutations result in mutant p53 proteins, some of which exhibit trans-dominant suppression over their wild type counterparts and lose their tumor suppressor properties.

Mutations in p53 could further diminish the effectiveness of doxorubicin, tamoxifen and other chemotherapeutic agents [12]. p53 has proven to be a promising target in the quest for novel anticancer strategies. p53 is considered as a major target of the chemotherapeutic drug cyclophosphamide (CP) which is an alkylating agent [32] and has been used in the present study. Numerous studies have demonstrated that the bioactive components from plants could have effectiveness in the battle against cancer. Curcumin, for example, has been studied to inhibit the mutations induced by cyclophosphamide in exon 7 of the TP53. Also, chlorophyllin has been found to have a powerful protective efficacy of 80% against CP induced mutations in the TP53 exon 7 [33]. UA, one such phytochemical has been studied to play a promising role in chemoprevention. Various investigations till now support this statement. Present study shows an immense chemoprotective role of UA against CP. Inspite of having low solubility and poor bioavailability, UA possess a vast array of pharmacological and toxicological activities. Future experiments are needed to further work on the mechanics involved in the restoration of wild-type- like properties to the p53 hot spot mutations. From all its reasonable to conclude that UA has shown a clear antimutagenic potential against cyclophosphamide in reverting the mutations in p53 gene.

 Acknowledgments

The authors are thankful to the Director, Centre of Research for Development, University of Kashmir for showing interest in this research work and permitting to carry out the research. The authors are also thankful to the Centre for Biodiversity and Taxonomy, University of Kashmir for the identification of the plant specimen.

Funding statement

This study did not receive any funding and the cost of research was met with by the authors.

Conflict of Interest

Authors declare no conflict of interest.

Ethical declaration

The study was approved by the Institutional Animals Ethics Committee [F (IAEC-Approval) KU/2017/21].

Author contribution

All authors contributed equally.

Data availability

The article contains all the essential data. Any other data or supporting documents etc. are available on request.

References 02 6381 07 15-16 358 1992 10.1038/358015a0 Lane D. P. Nature Cancer. p53, guardian of the genome 07 3 02 323-331 88 1997 10.1016/s0092-8674(00)81871-1 Levine A. J. Cell p53, the cellular gatekeeper for growth and division 13 53 12 7621-7636 18 1999 10.1038/sj.onc.1203285 May P. May E. Oncogene Twenty years of p53 research: structural and functional aspects of the p53 protein 01 3 03 a026104 6 2016 10.1101/cshperspect.a026104 Chen J Cold Spring Harbor Perspectives in Medicine The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression 5 05 1588-1593 174 2009 10.2353/ajpath.2009.080545 Klymkowsky MW Savagner P The American Journal of Pathology Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe 14 98 12 37137-37156 9 2018 10.18632/oncotarget.26440 Omar SI Tuszynski J Oncotarget The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants 5 05 573-580 9 2007 10.1038/ncb1571 Song H Hollstein M Xu Y Nature Cell Biology p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM 16 6 2020 10.1038/s41420-020-0251-x Amelio I Melino G Cell Death Discovery Context is everything: extrinsic signalling and gain-of-function p53 mutants 17 3 03 304-317 25 2014 10.1016/j.ccr.2014.01.021 Muller PAJ Vousden KH Cancer Cell Mutant p53 in cancer: new functions and therapeutic opportunities 10 10 701-713 9 2009 10.1038/nrc2693 Brosh R Rotter V Nature Reviews. Cancer When mutants gain new powers: news from the mutant p53 field 2 02 a001107 2 2010 10.1101/cshperspect.a001107 Oren M Rotter V Cold Spring Harbor Perspectives in Biology Mutant p53 gain-of-function in cancer 31 5 01 8921-8946 8 2017 10.18632/oncotarget.13475 Hientz K Mohr A Bhakta-Guha D Efferth T Oncotarget The role of p53 in cancer drug resistance and targeted chemotherapy 03 100671 49 2020 10.1016/j.drup.2019.100671 Cao X Hou J An Q Assaraf YG Wang X Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy Towards the overcoming of anticancer drug resistance mediated by p53 mutations 6 06 1578-1579 45 2007 10.1002/hep.21789 Beraza N Trautwein C Hepatology (Baltimore, Md.) Restoration of p53 function: a new therapeutic strategy to induce tumor regression? 29 7 12 1323-1334 127 2006 10.1016/j.cell.2006.12.007 Martins CP Brown-Swigart L Evan GI Cell Modeling the therapeutic efficacy of p53 restoration in tumors 22 10 2024 10.1038/nature05541 Ventura A Kirsch DG McLaughlin ME Tuveson DA Grimm J Lintault L et al ResearchGate Restoration of p53 function leads to tumor regression in vivo 3 03 282-288 8 2002 10.1038/nm0302-282 Bykov VJN Issaeva N Shilov A Hultcrantz M Pugacheva E Chumakov P Bergman J Wiman KG Selivanova G Nature Medicine Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound 26 34 08 30384-30391 280 2005 10.1074/jbc.M501664200 Bykov VJN Issaeva N Zache N Shilov A Hultcrantz M Bergman J Selivanova G Wiman KG The Journal of Biological Chemistry Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs 1407 4 2013 10.1038/ncomms2361 Wassman CD Baronio R Demir Ö Wallentine BD Chen C Hall LV Salehi F et al Nature Communications Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 15 5 05 614-625 21 2012 10.1016/j.ccr.2012.03.042 Yu X Vazquez A Levine AJ Carpizo DR Cancer Cell Allele-specific p53 mutant reactivation 1 06 70-80 2 2008 10.1016/j.molonc.2008.02.004 Zache N Lambert JMR Rökaeus N Shen J Hainaut P Bergman J Wiman K Bykov VJN Molecular Oncology Mutant p53 targeting by the low molecular weight compound STIMA-1 6 11 394-424 68 2018 10.3322/caac.21492 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A CA: a cancer journal for clinicians Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries 08 110254 128 2020 10.1016/j.biopha.2020.110254 Li C Wang X Chen T Wang W Yang Q Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie Trametes robiniophila Murr in the treatment of breast cancer 09 104631 168 2020 10.1016/j.pestbp.2020.104631 Huang J Sun W Seong KM Mittapalli O Ojo J Coates B Paige KN Clark JM Pittendrigh BR Pesticide Biochemistry and Physiology Dietary antioxidant vitamin C influences the evolutionary path of insecticide resistance in Drosophila melanogaster 01 01 257-263 270 2019 10.1016/j.foodchem.2018.07.111 Cao H Liu X Ulrih NP Sengupta PK Xiao J Food Chemistry Plasma protein binding of dietary polyphenols to human serum albumin: A high performance affinity chromatography approach 9 09 745-756 3 2003 10.1038/nri1184 Aggarwal BB Nature Reviews. Immunology Signalling pathways of the TNF superfamily: a double-edged sword 11 104735 147 2020 10.1016/j.fitote.2020.104735 Sun Q He M Zhang M Zeng S Chen L Zhou L Xu H Fitoterapia Ursolic acid: A systematic review of its pharmacology, toxicity and rethink on its pharmacokinetics based on PK-PD model 15 09 268-275 811 2017 10.1016/j.ejphar.2017.06.030 Bergamin LS Figueiró F Dietrich F Manica FDM Filippi-Chiela EC Mendes FB Jandrey EHF Lopes DV Oliveira FH Nascimento IC Ulrich H Battastini AMO European Journal of Pharmacology Interference of ursolic acid treatment with glioma growth: An in vitro and in vivo study 01 130-149 103 2018 10.1016/j.foodres.2017.10.028 López-Hortas L Pérez-Larrán P González-Muñoz MJ Falqué E Domínguez H Food Research International (Ottawa, Ont.) Recent developments on the extraction and application of ursolic acid. A review 1 01 113-119 9 2009 10.1016/j.intimp.2008.10.013 Jang S Yee S Choi J Choi M Do G Jeon S Yeo J Kim M Seo K Lee M International Immunopharmacology Ursolic acid enhances the cellular immune system and pancreatic beta-cell function in streptozotocin-induced diabetic mice fed a high-fat diet 1 1989 Higuchi R Perkin Elmer/Cetus Newsletter Rapid, efficient DNA extraction for PCR from cells or blood 2764-72 10 268 2001 10.1046/j.1432-1327.2001.02225.x Appella E Anderson CW Eur J Biochem Post‐translational modifications and activation of p53 by genotoxic stresses 11-12 857-863 63 2008 10.1515/znc-2008-11-1213 Gouda EM Elbehairy AM Ghoneim MA Zeitschrift Fur Naturforschung. C, Journal of Biosciences Antimutagenic efficacy of some natural compounds on cyclophosphamide-induced p53 alterations